Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 Pharmaceutical 2016
"Partnerships,
Licensing, Investments and M&A Deals and Trends in
Pharmaceuticals - Q3 2016"
The Report covers current Market Trends, Worldwide Analysis, Global
Forecast, Review, Share, Size, Growth, Effect.
Description-
GlobalData's
Partnerships, Licensing, Investments and M&A Deals and Trends in
Pharmaceuticals - Q3 2016 report is an essential source of data and
trend analysis on partnerships, licensing, mergers and acquisitions
(M&As) and financings in the pharmaceuticals industry. The report
provides detailed information on partnership and licensing
transactions, M&As, equity/debt offerings, private equity, and
venture financing registered in the pharmaceuticals industry in Q3
2016. The report portrays detailed comparative data on the number of
deals and their value in the last five quarters, subdivided by deal
types, various therapy areas, and geographies. Additionally, the
report provides information on the top financial advisory firms in
the pharmaceuticals industry.
Data
presented in this report is derived from GlobalDatas proprietary
in-house Pharmaceuticals eTrack deals database and primary and
secondary research.
Scope
-
Analysis of the market trends for the pharmaceutical industry in the
global arena.
-
Review of deal trends in the cardiovascular, central nervous system,
dermatology, ear nose throat disorders, gastrointestinal, genito
urinary system and sex hormones, hematological disorders, hormonal
disorders, immunology, infectious disease, male health, metabolic
disorders, mouth and dental disorders, musculoskeletal, oncology,
ophthalmology, respiratory, toxicology, and women's health segments.
-
Analysis of partnerships, licensing, M&As, equity/debt offerings,
private equity, and venture financing deals in the pharmaceutical
industry.
-
Analysis of therapy areas which are very active in terms of venture
capital financing, partnerships, licensing agreements, equity/debt
offerings, and M&As.
-
Analysis of deals based on different payment modes, including upfront
and milestone payments, primarily in partnerships and licensing
agreements in the pharmaceutical industry.
-
Analysis of partnership and licensing deals based on clinical stage
of development of products.
-
Summary of the pharmaceutical deals globally in the five quarters.
-
Information on the top deals happened in the pharmaceutical industry.
-
Geographies covered include - North America, Europe, Asia Pacific,
South & Central America, and the Middle East & Africa.
-
League tables of financial advisors in M&As and equity/debt
offerings. This includes key advisors such as Morgan Stanley, Credit
Suisse, and Goldman Sachs
Reasons
to buy
-
Enhance your decision making capability in a more rapid and time
sensitive manner.
-
Find out the major deal performing segments for investments in your
industry.
-
Evaluate the types of companies which are entering into partnership
or licensing agreements; divesting and acquiring assets.
-
Identify companies that are aggressively looking to raise capital in
the market
-
Evaluate niche therapy areas that are receiving majority of the
upfront and milestone payments in the pharmaceutical industry.
-
Identify the key venture capitalists, who are financing the
pharmaceutical and biotech companies.
-
Evaluate the clinical development stages where majority of the
partnerships and licensing agreements are happening.
-
Do deals with an understanding of how competitors are financed, and
the mergers and partnerships that have shaped the pharmaceutical
industry.
-
Identify growth segments and opportunities in each region within the
industry.
-
Look for key financial advisors where you are planning to raise
capital from the market or for acquisitions within the industry.
Comments
Post a Comment